AIM: to evaluate the therapeutic efficacy of oxaliplatin and to analyze the pharmacokinetics of both ultrafiltrable (free) and protein-bound platinum in patients with metastatic colon cancer. METHOD: 60 patients with stage IV colon carcinoma received 4-6 (mean 4.5) cycles of oxaliplatin based combination chemotherapy. Response rate, progression-free survival (PFS) and toxicity were evaluated. The pharmacokinetics of oxaliplatin was evaluated in 8 patients who were given 85 mg/sqm or 130 mg/sqm using an infusion time of 2-4 h. Pharmacokinetic analysis was performed on blood, plasma and plasma ultrafiltrable by ICP-MS (Inductively Coupled Plasma Mass Spectrometry). RESULTS: Overall response rate (complete and partial) occurred in 33 (55%) patients. The median time of progression was 9.3 months. Cumulative neurotoxicity, vomiting and diarrhea, myelosuppression appeared in 32.3%, 21.3%, and 39.4% patients, respectively. The mean Cmax and AUC 0-24 of oxaliplatin increased in a dose-related manner. The pharmacokinetics of platinum after oxaliplatin administration was triphasic characterized by a short initial distribution phase and a long terminal elimination phase.The clearance of ultrafiltrable platinum was relatively high and the clearance of platinum from plasma and blood cells was relatively low, which is probably a reflection of the covalent binding of platinum to these matrices. CONCLUSION: Oxaliplatin is active and well tolerated in patients with advanced colon cancer. With a relatively low interpatient variability, it is eliminated triphasically and the mean Cmax and AUC 0-24 increases in a dose-related manner. These results provide a scientific basis for the safe and effective use of oxaliplatin in the clinic.
AIM: to evaluate the therapeutic efficacy of oxaliplatin and to analyze the pharmacokinetics of both ultrafiltrable (free) and protein-bound platinum in patients with metastatic colon cancer. METHOD: 60 patients with stage IV colon carcinoma received 4-6 (mean 4.5) cycles of oxaliplatin based combination chemotherapy. Response rate, progression-free survival (PFS) and toxicity were evaluated. The pharmacokinetics of oxaliplatin was evaluated in 8 patients who were given 85 mg/sqm or 130 mg/sqm using an infusion time of 2-4 h. Pharmacokinetic analysis was performed on blood, plasma and plasma ultrafiltrable by ICP-MS (Inductively Coupled Plasma Mass Spectrometry). RESULTS: Overall response rate (complete and partial) occurred in 33 (55%) patients. The median time of progression was 9.3 months. Cumulative neurotoxicity, vomiting and diarrhea, myelosuppression appeared in 32.3%, 21.3%, and 39.4% patients, respectively. The mean Cmax and AUC 0-24 of oxaliplatin increased in a dose-related manner. The pharmacokinetics of platinum after oxaliplatin administration was triphasic characterized by a short initial distribution phase and a long terminal elimination phase.The clearance of ultrafiltrable platinum was relatively high and the clearance of platinum from plasma and blood cells was relatively low, which is probably a reflection of the covalent binding of platinum to these matrices. CONCLUSION:Oxaliplatin is active and well tolerated in patients with advanced colon cancer. With a relatively low interpatient variability, it is eliminated triphasically and the mean Cmax and AUC 0-24 increases in a dose-related manner. These results provide a scientific basis for the safe and effective use of oxaliplatin in the clinic.
Authors: Robin J Lurvink; Rudaba Tajzai; Koen P Rovers; Emma C E Wassenaar; Dirk-Jan A R Moes; Giulia Pluimakers; Djamila Boerma; Jacobus W A Burger; Simon W Nienhuijs; Ignace H J T de Hingh; Maarten J Deenen Journal: Ann Surg Oncol Date: 2020-06-22 Impact factor: 5.344
Authors: Loek A W de Jong; Fortuné M K Elekonawo; Marie Lambert; Jan Marie de Gooyer; Henk M W Verheul; David M Burger; Johannes H W de Wilt; Etienne Chatelut; Rob Ter Heine; Philip R de Reuver; Andre J A Bremers; Nielka P van Erp Journal: Cancer Chemother Pharmacol Date: 2020-06-27 Impact factor: 3.333
Authors: George M Ramzy; Laura Boschung; Thibaud Koessler; Céline Delucinge-Vivier; Mylène Docquier; Thomas A McKee; Laura Rubbia-Brandt; Patrycja Nowak-Sliwinska Journal: Cancers (Basel) Date: 2022-09-30 Impact factor: 6.575
Authors: Annick De Weerdt; Amélie Dendooven; Annemie Snoeckx; Jan Pen; Martin Lammens; Philippe G Jorens Journal: BMC Cancer Date: 2017-08-29 Impact factor: 4.430